Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer
By:
Authors
Jiwon Choi
College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea
National Center for Efficacy Evaluation for Respiratory Disease Products, Korea Institute of Toxicology, Seoul, Republic of Korea
Jiyoung Park
College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea
National Center for Efficacy Evaluation for Respiratory Disease Products, Korea Institute of Toxicology, Seoul, Republic of Korea
Ilyoung Cho
College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea
Yhunyhong Sheen
College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea
Language: English
Page range: 185 - 197
Submitted on: Sep 26, 2021
Accepted on: Jan 28, 2022
Published on: Apr 7, 2022
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2022 Jiwon Choi, Jiyoung Park, Ilyoung Cho, Yhunyhong Sheen, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.